Food Shouldn’t Hurt: Why Eupraxia Pharmaceuticals Is Building a More Precise EoE Investment Story -( $EPRX $MRNA $MRK $REGN $SNY $TAK $XBI )

Tribe Public CEO Presentation & Q&A: Hosted Friday, August 21

Tribe Public hosted its CEO Presentation and Q&A webinar, “Food Shouldn’t Hurt: EOE, Eupraxia, and a Promising New Treatment Approach,” featuring James Helliwell, MD, Chief Executive Officer of Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX). The discussion focused on eosinophilic esophagitis (EoE), Eupraxia’s investigational EP-104GI program and the company’s proprietary Diffusphere™ technology platform. In a disease where eating can become an exercise in caution rather than enjoyment, Eupraxia advances a therapeutic concept aimed at making treatment more localized, durable and patient-friendly. The webinar event was structured as an efficient approximately 30-minute session, followed by a brief Q&A. In biotech, as in fine dining, brevity is welcome—provided the substance remains satisfying.

A Chronic Disease With a Growing Need

EoE is a chronic inflammatory disease of the esophagus that can lead to painful swallowing, difficulty swallowing and food impaction. The condition’s impact reaches beyond a clinical diagnosis: for many patients, routine meals become a source of anxiety and discomfort. Eupraxia highlights the significant unmet need in EoE, a disease affecting hundreds of thousands of people in the United States. The investment opportunity becomes increasingly visible as physician awareness, diagnosis and available treatments continue to expand. Existing approved therapies, including Dupixent from Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NASDAQ: SNY), along with Eohilia from Takeda Pharmaceutical Company Limited (NYSE: TAK), help validate EoE as a growing and commercially meaningful therapeutic category. The U.S. EoE market is forecast to reach $1.19 billion by 2030. That market validation makes Eupraxia’s strategy worth watching. The company does not merely pursue another approach to inflammation. It seeks to address the location and duration of treatment delivery.

The Case for Local Delivery

Eupraxia describes Diffusphere™ as a proprietary polymer-based microsphere platform designed to enable localized and extended-release delivery of drugs. The theory behind the platform is direct: deliver treatment to the tissue physicians intend to treat, sustain its effect and potentially reduce drug exposure outside the desired target area. For EP-104GI, the company applies that concept through direct administration into the esophageal wall. The investigational product is designed to provide a locally delivered, extended-duration anti-inflammatory effect in the tissue affected by EoE. The objective is to improve the therapeutic experience in a chronic disease where the treatment burden can be nearly as tiresome as the condition itself. The platform story also extends beyond EoE. Eupraxia outlines how Diffusphere™ could potentially support additional therapeutic opportunities by pairing localized, sustained-release delivery with both existing and novel drug compounds. Those opportunities remain developmental and subject to clinical, regulatory and commercial risks, but they reinforce the possibility that the company may become more than a one-asset biotech story.

EP-104GI Is the Central Clinical Catalyst

EP-104GI is being studied in Eupraxia’s RESOLVE trial, a Phase 1b/2 clinical program evaluating treatment in adults with active EoE. The Phase 2b portion of RESOLVE is a randomized, placebo-controlled trial evaluating two active-dose arms against placebo, with patients followed for 52 weeks. The study is designed to enroll at least 60 patients across up to 25 global sites. Key assessments include histology, peak eosinophil counts, patient-reported symptoms, safety and tolerability—measures that can help determine whether the program delivers not only biological activity but also an improvement patients can feel in day-to-day life. Earlier Phase 1b/2a data reported by Eupraxia supported advancement into the placebo-controlled portion of the study. The company reports dose-related improvement trends in symptoms and tissue-health measures, with encouraging findings in selected higher-dose cohorts. Those data are preliminary, based on small cohorts and require confirmation in the randomized Phase 2b study. For investors, the central future milestone remains top-line data from the Phase 2b RESOLVE trial, which Eupraxia expects in the third quarter of 2026. That readout represents a consequential test of whether localized, extended-release delivery can create a differentiated clinical profile in EoE.

A Differentiated EoE Opportunity

The bullish investment case around Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) rests on the potential for EP-104GI to establish a distinct treatment profile in a disease with growing commercial validation.

If successful in controlled trials, the program could potentially offer:

• Localized treatment directed toward affected esophageal tissue
• Extended-release drug delivery designed to lengthen therapeutic effect
• A potentially differentiated non-systemic approach, subject to clinical validation
• Exposure to a growing EoE market supported by increasing awareness and established therapies
• A possible platform-based expansion opportunity through Diffusphere™

The presence of commercially available therapies in EoE also serves as an important point of validation. Competition in a therapeutic market can be inconvenient for a spreadsheet, but it often makes the commercial case more credible. It signals that physicians recognize the disease, patients are being diagnosed and payers are beginning to engage with treatment options. Eupraxia’s strategic question is whether its local-delivery approach can earn a differentiated position in that evolving treatment landscape.

Financial Runway Supports Execution

Eupraxia reports $52.4 million in cash and cash equivalents and $81.2 million in short-term investments as of June 30, 2026. The company indicates that its capital resources are expected to fund operations into the second half of 2028. That projected runway gives Eupraxia additional flexibility as it advances toward its anticipated Phase 2b catalyst and considers next-stage development planning. It does not remove the potential for future capital raises or shareholder dilution—few clinical-stage biotech companies enjoy that luxury—but it reduces the immediacy of financing pressure heading into a pivotal data period.

Key Takeaways

The Tribe Public discussion provides investors an opportunity to consider several defining issues:

• The unmet need for more durable and differentiated EoE treatments
• EP-104GI’s potential role as a localized, extended-release therapeutic candidate
• The importance of upcoming placebo-controlled Phase 2b RESOLVE data
• The broader strategic potential of the Diffusphere™ platform
• Eupraxia’s capital position as it moves toward clinical milestones

The investment thesis is not that EoE is transformed by a single presentation—or by one clinical program. It is that Eupraxia advances a thoughtful drug-delivery strategy toward a meaningful clinical and commercial opportunity in an increasingly recognized disease market. For investors tracking EPRX, the upcoming Phase 2b data remains the next major proving ground. If EP-104GI demonstrates a favorable combination of efficacy, tolerability and durability in controlled data, Eupraxia’s localized-delivery model could move from an intriguing scientific premise to a substantially more investable clinical story.

The Sources

1. Eupraxia Pharmaceuticals — Corporate Website
2. Tribe Public — Disclaimers
3. GlobalData: U.S. Eosinophilic Esophagitis Market Forecast
4. Pharmaceutical Technology: U.S. EoE Market Expected to Reach $1.19 Billion by 2030
5. Eupraxia Pharmaceuticals Q2 2026 Financial Results
6. Eupraxia Pharmaceuticals Q1 2026 Financial Results
7. Eupraxia Announces Positive RESOLVE Phase 1b/2a Data for EP-104GI
8. Eupraxia Doses First Patient in Phase 2b Placebo-Controlled RESOLVE Trial
9. Eupraxia Reports Additional 52-Week Follow-Up Data From RESOLVE
10. Eupraxia Form F-10/A — Universal Shelf Registration Statement
11. Eupraxia 6-K Filing and Financial Position
12. Eosinophilic Esophagitis Market Size and Forecast

Important Disclosure

This content is for informational and educational purposes only and does not constitute investment advice, a solicitation or an offer to buy or sell securities. Eupraxia is a clinical-stage biotechnology company, and EP-104GI is investigational; it has not been approved by the U.S. Food and Drug Administration. Early-stage and preliminary clinical results may not be replicated in later-stage trials. Biotech investing involves substantial clinical, regulatory, financing, dilution and market risks. Tribe Public states that it is compensated by corporations for investor-education event coordination and dissemination. Tribe Public, its officers or affiliated entities may hold interests in companies discussed. Investors should review applicable SEC and SEDAR+ filings, consider all disclosed risk factors and consult qualified financial professionals before making investment decisions.